All In Biotech

NDA 022465 · Novartis

Votrient

Pazopanib Hydrochloride · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jan 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Oct 19, 2009

Approved uses

4

Original approval plus efficacy supplements

Registered trials

272

22 Phase 3, 12 recruiting

FAERS reports

22,529

13,736 serious, 6,020 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended [see Warnings and Precautions (5.1)]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. ( 5.1 )

What it is approved for

From the label in effect Dec 16, 2025.

VOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma VOTRIENT ® is indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.

Mechanism: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VOTRIENT · PAZOPANIB HYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription · TE AB
  • VOTRIENT · PAZOPANIB HYDROCHLORIDE EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Pazopanib" as an intervention, any sponsor and status, largest first.

All 272 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death4,278
  • diarrhoea3,309
  • fatigue2,226
  • nausea2,199
  • decreased appetite1,272
  • vomiting1,228
  • drug ineffective1,227
  • malignant neoplasm progression1,168
  • hypertension1,080
  • malaise822
  • weight decreased815
  • asthenia804

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
2010212
2011694
2012968
20131,676
20142,372
20153,187
20162,244
20172,435
20182,329
20192,003
20201,398
20211,136
2022850
2023615
2024198
2025113
202698

Recalls

1 FDA enforcement reports for this application.

  • Nov 20, 2023 · Class III · Completed

    Failed Dissolution Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Votrient (Pazopanib HCl)

2024 spending

$22.2M

Beneficiaries

409

1,939 claims

Per beneficiary

$54,275

$135.89 per unit

View as table
YearSpending
2020$147,821,583
2021$126,114,097
2022$106,613,649
2023$97,957,715
2024$22,198,389

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 392 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.